Evidence map›Paper›PMID 30076230›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Selective Na

Kay L Richards, Carol J Milligan, Robert J Richardson, Nikola Jancovski, Morten Grunnet, Laura H Jacobson, Eivind A B Undheim, Mehdi Mobli, Chun Yuen Chow, Volker Herzig and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 135 citations in OpenAlex.

  1. Review
  2. Review
  3. Characterization of the R893C NaFrontiers in cardiovascular medicine · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Dravet syndrome: novel insights intoFrontiers in neuroscience · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Brain expression profiles of twoTranslational neuroscience · 2024
    Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Kay L RichardsIon Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia.
Carol J MilliganIon Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia.
Robert J RichardsonIon Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia.
Nikola JancovskiIon Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia.
Morten GrunnetNeuroscience Drug Discovery, H. Lundbeck A/S, DK-2500 Valby, Denmark.
Laura H JacobsonSleep and Cognition Group, Epilepsy Division, Florey Insitute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia.
Eivind A B UndheimCentre for Advanced Imaging, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-8667-3999
Mehdi MobliCentre for Advanced Imaging, The University of Queensland, Brisbane, QLD 4072, Australia.
Chun Yuen ChowInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-2861-5843
Volker HerzigInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Agota CsotiDepartment of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Gyorgy PanyiDepartment of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Christopher A ReidIon Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia.
Glenn F KingInstitute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia; glenn.king@imb.uq.edu.au spetrou@unimelb.edu.au.ORCID 0000-0002-2308-2200
Steven PetrouIon Channels and Disease Group, Florey Institute of Neuroscience and Mental Health, Parkville, VIC 3010, Australia; glenn.king@imb.uq.edu.au spetrou@unimelb.edu.au.
The University of Queensland · AUFlorey Institute of Neuroscience and Mental Health · AUThe University of Melbourne · AUUniversity of Debrecen · HUUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dravet syndrome is a catastrophic, pharmacoresistant epileptic encephalopathy. Disease onset occurs in the first year of life, followed by developmental delay with cognitive and behavioral dysfunction and substantially elevated risk of premature death. The majority of affected individuals harbor a loss-of-function mutation in one allele of

Indexed as

MutationAnimalsCHO CellsCricetulusEpilepsies, MyoclonicHEK293 CellsHumansInterneuronsMiceMice, Mutant StrainsNAV1.1 Voltage-Gated Sodium ChannelSpider VenomsSynaptic TransmissionNAV1.1 Voltage-Gated Sodium ChannelScn1a protein, mouseSpider VenomsDravet syndromegenetic epilepsyseizuresspider venomtargeted drug therapy

Identifiers

PMID30076230
PMCPMC6112713
OpenAlexW2885328146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.